Increased brain metabolism after acute administration of the synthetic cannabinoid HU210: A small animal PET imaging study with 18F-FDG

Brain Research Bulletin

Volumn 87, Issue 2-3, 2012, Pages 172-179

  Nguyen, Vu H ^a   Verdurand, Mathieu ^a,b   Dedeurwaerdere, Stefanie ^a,c   Wang, Hongqin ^a,d   Zahra, David ^a   Gregoire, Marie Claude ^a   Zavitsanou, Katerina ^a  

^a AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

^b SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

18F FDG; CB1 receptors; Glucose metabolism; HU210; PET; Rat

Indexed keywords

DEXANABINOL; FLUORODEOXYGLUCOSE F 18; GLUCOSE;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN METABOLISM; BRAIN REGION; CEREBELLUM; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORPUS STRIATUM; FRONTAL CORTEX; GLUCOSE METABOLISM; HIPPOCAMPUS; HYPOTHALAMUS; IN VIVO STUDY; MALE; MEDIAL GENICULATE BODY; NEUROMODULATION; NONHUMAN; OLIVARY NUCLEUS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; THALAMUS;

ANALYSIS OF VARIANCE; ANIMALS; BRAIN; BRAIN MAPPING; FLUORODEOXYGLUCOSE F18; MALE; NEUROPROTECTIVE AGENTS; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, WISTAR; TETRAHYDROCANNABINOL; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84856596198     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2011.11.011     Document Type: Article

References (52)

1. 1-tetrahydrocannbinol and other cannabinoids with emphasis on man. Pharmacol. Rev. 1986, 38:21-43.
2. Bloom A.S., Tershner S., Fuller S.A., Stein E.A. Cannabinoid-induced alterations in regional cerebral blood flow in the rat. Pharmacol. Biochem. Behav. 1997, 57:625-631.
3. Brewster M.E., Pop E., Foltz R.L., Reuschel S., Griffith W., Amselem S., Biegon A. Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers. Int. J. Clin. Pharmacol. Ther. 1997, 35(9):361-365.
4. Brown M.S., Anderson R.G., Goldstein J.L. Recycling receptors: the round-trip itinerary of migrant membrane proteins. Cell 1983, 32:663-667.
5. Bruehl C., Witte O.W. Cellular activity underlying altered brain metabolism during focal epileptic activity. Ann. Neurol. 1995, 38:414-420.
6. Bustamante E., Pedersen P.L. High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. Proc. Natl. Acad. Sci. U.S.A. 1977, 74(9):3735-3739.
7. Caspi A., Moffitt T.E., Cannon M., McClay J., Murray R., Harrington H., Taylor A., Arseneault L., Williams B., Braithwaite A., Poulton R., Craig I.W. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene×environment interaction. Biol. Psychiatry 2005, 57:1117-1127.
8. Chang L., Chronicle E.P. Functional imaging studies in cannabis users. Neuroscientists 2007, 13(5):422-432.
9. Chatziioannou A.F., Cherry S.R., Shao Y., Silverman R.W., Meadors K., Farquhar T.H., Pedarsani M., Phelps M.E. Performance evaluation of micro PET: a high-resolution Lutetium Oxyorthosolicate PET scanner or animal imaging. J. Nucl. Med. 1999, 40:1164-1175.
10. Cherry S.R., Shao Y., Silverman R.W., Meadors K., Siegel S., Chatziiannou A., Young J.W., Jones W., Moyers J.C., Newport D., Boutefnouchet A., Farquhar T.H., Andreaco M., Paulus M.J., Binkley D.M., Nutt R., Phelps M.E. MicroPET: a high resolution PET scanner for imaging small animals. IEEE Trans. Nucl. Sci. 1997, 44:1161-1166.
11. Chugani H.T., Rintahaka P.J., Shewmon D.A. Ictal patterns of cerebral glucose utilization in children with epilepsy. Epilepsia 1994, 35:813-822.
12. Chvatchko Y., Howard I., Riezman H. Two yeast mutants defective in endocytosis are defective in pheromone response. Cell 1986, 46:355-364.
13. Dalton V.S., Wang H., Zavitsanou K. HU210-induced downregulation in cannabinoid CB1 receptor binding strongly correlates with body weight loss in the adult rat. Neurochem. Res. 2009, 34:1343-1353.
14. Dawson N., Ferrington L., Olverman H.J., Kelly P.A. Novel analysis for improved validity in semi-quantitative 2-deoxyglucose autoradiographic imaging. J. Neurosci. Methods 2008, 175:25-35.
15. De Vry J., Jentzsch K.R., Kuhl E., Eckel G. Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development. Behav. Pharmacol. 2004, 15:1-12.
16. Dedeurwaerdere S., Wintmolders C., Straetemans R., Pemberton D., Langlois X. Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist. Psychopharmacology 2011, 214:505-514.
17. Dewey W. Cannabinoid pharmacology. Pharmacol. Rev. 1986, 38:151-178.
18. Ferrari F., Ottani A., Giuliani D. Influence of the cannabinoid agonist HU210 on cocaine- and CQP-201-403-induced behavioural effects in rat. Life Sci. 1999, 65:823-831.
19. Ferrari F., Ottani A., Giuliani D. Cannabimimetic activity in rats and pigeons of HU210, a potent antiemetic drug. Pharmacol. Biochem. Behav. 1999, 62:75-80.
20. Ferrari F., Ottani A., Vivoli R., Giuliani D. Learning impairment produced in rats by the cannabinoid agonist HU210 in a water-maze task. Pharmacol. Biochem. Behav. 1999, 64:555-561.
21. Ferrari F., Ottani A., Giuliani D. Inhibitory effect of the cannabinoid agonist HU210 on rat sexual behaviour. Physiol. Behav. 2000, 69:547-554.
22. Ferraro L., Tomasini M.C., Gessa G.L., Bebe B.W., Tanganelli S., Antonelli T.T. The cannabinoid receptor agonist WIN 55,212-2 regulates glutamate transmission in rat cerebral cortex: an in vivo and in vitro study. Cereb. Cortex 2001, 11:728-733.
23. Ferraro L., Tomasini M.C., Cassano T., Bebe B.W., Sniniscalchi A., O'Commor W.T., Magee P., Tanganelli S., Cuomo V., Antonelli T. Cannabinoid receptor agonist WIN 55,212-2 inhibit rat cortical diasylate gamma-aminobutyric acid levels. J. Neurosci. Res. 2001, 66:298-302.
24. 9-tetrahydrocannabinol on rates of local cerebral glucose utilization in rat. Synapse 2002, 45:134-142.
25. Geisow M.J. Intracellular membrane traffic. Nature 1982, 295:649-650.
26. Glass M., Brotchie J.M., Maneuf Y.P. Modulation of neurotransmission by cannabinoids in the basal ganglia. Eur. J. Neurosci. 1997, 9:199-203.
27. Gonzales S., Cebeira M., Fernandez-Ruiz J. Cannabinoid tolerance and dependence: review of studies in laboratory animals. Pharmacol. Biochem. Behav. 2005, 81:300-318.
28. Greer C.A., Stewart W.B., Kauer J.S., Shepherd G.M. Tomographical and laminar localization of 2-deoxyglucose uptake in rat olfactory bulb induced by electrical stimulation of olfactory nerves. Brain Res. 1981, 217(2):279-293.
29. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., De Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 1991, 11:563-583.
30. Hsieh C., Brown S., Derleth C., Mackie K. Internalization and recycling of the CB1 cannabinoid receptor. J. Neurochem. 1999, 73:493-501.
31. Kalemis A., Binnie D.M., Flower M.A., Ott R.J. Image intensity normalisation by maximising the Siddon line integral in the joint intensity distribution space. Med. Image Anal. 2009, 13:900-909.
32. Lichtman A.H., Martin B.R. Cannabinoid tolerance and dependence. Handb. Exp. Pharmacol. 2005, 168:691-717.
33. Lucignani G., Schmidt K., Moresco R.M., Striano G., Colombo F., Sokoloff L., Fazio F. Measurement of regional cerebral glucose utilization with fluorine-18-FDG and PET in heterogenerous tissues: theoretical considerations and practical procedure. J. Nucl. Med. 1993, 34:360-366.
34. 9-Tetrahydrocannabinol alters cerebral metabolism in a biphasic, dose-dependent manner in rat brain. Eur. J. Pharmacol. 1991, 202:373-378.
35. Martini L., Waldhoer M., Pusch M., Kharazia V., Fong J., Lee J.H., Freissmuth C., Whistler J.L. Ligand-induced down-regulation of the cannabinoid 1 receptor is mediated by the G-protein-coupled receptor-associated sorting protein GASP1. FASEB J. 2007, 21:802-811.
36. Medina K.L., Hanson K.L., Schweinsburg A.D., Cohen-Zion M., Nagel B.J., Tapert S.F. Neuropsychological functioning in adolescent marijuana users: subtle deficits detectable after a month of abstinence. J. Int. Neuropsychol. Soc. 2007, 13:807-820.
37. Ottani A., Giuliani D. HU210: a potent tool for investigations of the cannabinoid system. CNS Drug Rev. 2001, 7:131-145.
38. 9-Tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res. 2002, 948:155-158.
39. 18F-FDG in rodents. J. Nucl. Med. 2007, 48(2):277-287.
40. Schmidt K.C., Lucignani G., Sokoloff L. Fluorine-18-fluorodeoxyglucose PET to determine regional cerebral glucose utilization: a re-examination. J. Nucl. Med. 1996, 37(2):394-399.
41. 18F]fluorodeoxyglucose method. J. Cereb. Blood Flow Metab. 1992, 12:823-834.
42. Schneider D.L. ATP-dependent acidification of intact and disrupted lysosomes. Evidence for an ATP-driven proton pump. J. Biol. Chem. 1981, 256:3858-3862.
43. Sim-Selley L.J. Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit. Rev. Neurobiol. 2003, 15:91-119.
44. Sim-Selley L.J., Schechter N.S., Rorrer W.K., Dalton G.D., Hernandez J., Martin B.R., Selley D.E. Prolonged recovery rate of CB1 receptor adaptation after cessation of long-term cannabinoid administration. Mol. Phamacol. 2006, 70(3):896-996.
45. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J. Neurochem. 1977, 28:897-916.
46. Tan C.M., Brady A.E., Nickols H.H., Wang Q., Limbird L.E. Membrane trafficking of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 2004, 44:559-609.
47. 18F]fluorodeoxyglucose: theory. implementation, and optimization procedures. J. Cereb. Blood Flow Metab. 1994, 14:406-422.
48. Visser E.P., Disselhorst J.A., Brom M., Laverman P., Gotthardt M., Oyen W.J.G., Boerman O.C. Spatial resolution and sensitivity of the Inveon small-animal PET scanner. J. Nucl. Med. 2009, 50:139-147.
49. 18F-2-Fluoro-2-deoxyglucose. Psychiatry Res. Neuroimaging 1991, 40:69-78.
50. Volkow N.D., Gillespie H., Mullani N., Tancredi L., Grant C., Valentine A., Hollister L. Brain glucose metabolism in chronic marijuana users at baseline and during marijuana intoxication. Psychiatry Res. 1996, 67(1):29-39.
51. 9-tetrahydrocannabinol and marijuana in humans. Psychopharmacology 2002, 161:331-339.
52. 9-tetrahydrocannabinol administration in the rat. Psychopharmacology 2002, 161:129-136.